Monitor upcoming earnings or pipeline updates for signs of improved operational execution or partnership activity that may result from the leadership change. Absent financial or strategic catalysts, this promotion is a routine internal realignment with limited near-term trading implications.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $4.18entry
- T+1 · 7mo ago +3.35%α +3.83% · $4.32
- T+5 · 7mo ago +9.33%α +8.93% · $4.57
- T+20 · 6mo ago −1.67%α −6.63% · $4.11
- T+60 · 4mo ago −27.27%α −32.05% · $3.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion A/S announced the promotion of Birgitte Rn from Chief Scientific Officer (CSO) to a dual role as CSO and Chief Operating Officer (COO), citing organizational alignment and her long-standing operational and scientific contributions. The move is intended to enhance external engagement and strategy execution around its AI-Immunology platform.
Key Facts
- Birgitte Rn promoted from CSO to joint CSO and COO role at Evaxion A/S
- Promotion follows internal management review aimed at improving external visibility and strategic execution
- No changes to other executive roles; management team remains stable
- No financial terms, compensation changes, or structural reorganization disclosed
- Filing consists solely of a press release with no material financial or operational updates
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Expanded responsibilities without additional team changes could strain leadership capacity
- Lack of external hires or structural changes may limit impact on investor engagement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002722 |
| Exhibit: exh_991.htm | 0001171843-26-002722 |
| Document: 0001171843-26-002722-index-headers.html | 0001171843-26-002722 |
| Document: 0001171843-26-002722-index.html | 0001171843-26-002722 |
| Document: 0001171843-26-002722.txt | 0001171843-26-002722 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers